Phosphatidylserine
Of 853 on-market phosphatidylserine products in the January 2026 DSLD dump, the median declared dose is 100 mg, and 95.7% list unspecified/undisclosed form as the primary form.
Form share
Of 837 products with an identifiable primary form, here is the share held by each form of Phosphatidylserine on the market today.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
| Form | Quality tier | n | Share |
|---|---|---|---|
| unspecified/undisclosed form | Unrated | 801 | 95.7% |
| Phosphatidylserine complex / lecithin concentrate (PS content is a percentage of the declared mass) | Unrated | 36 | 4.3% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 546 products with a disclosed amount.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
- 13.7% of products fall below the fairy-dust threshold (20 mg, 20% of the studied low dose).
- 32.9% of products don't disclose an amount because Phosphatidylserine is declared inside a proprietary blend.
Where does your dose rank?
Enter a per-serving dose (mg) to see exactly how it compares to the 546 on-market phosphatidylserine products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.
By dosage form
By target group
Top brands
Search interest over time
How often people search for phosphatidylserine on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.
Or see this search directly on trends.google.com.
Forms explained
Label discloses phosphatidylserine mass without distinguishing soy-, sunflower- or other-derived material (raw_form often says "Soy" or "Sunflower Lecithin"); no verified head-to-head comparison between sources.
Source: Kato-Kataoka A et al. 2010, J Clin Biochem Nutr 47(3):246-255, PMID 21103034 (soy-derived); Friling M et al. 2025, Nutr J 25(1):3, PMID 41318468 (sunflower-derived, 100 mg/day in children, no difference in primary outcomes)
The declared mass is the carrier/concentrate (labels note PS at 1-70% of it), so it cannot be read as mg of phosphatidylserine; recorded without a dose.
Reference values
- RDA (adult): not established — Phospholipid made by the body and present in food; no RDA/AI exists.
- Tolerable Upper Intake Level (adult): not established — Not established. In the RCTs cited below no adverse effects were attributed to soy- derived PS at 100-300 mg/day for 6 months (Kato-Kataoka 2010, PMID 21103034, as stated in the abstract); this is a trial observation, not an upper limit.
- Studied clinical dose range: 100–600 mg
- Kato-Kataoka A et al. 2010, J Clin Biochem Nutr 47(3):246-255, PMID 21103034 -- double- blind RCT (n=78, ages 50-69 with memory complaints), soy-derived PS 100 mg or 300 mg/day vs placebo x6 months; neuropsychological scores rose in all groups, but in the subgroup with lower baseline scores memory scores (delayed verbal recall) rose significantly in the PS groups vs baseline while placebo stayed flat. Counter-evidence at the high end: Jorissen BL et al. 2001, Nutr Neurosci 4(2):121-134, PMID 11842880 -- RCT (n=120, age >57 with age-associated memory impairment), soy-derived PS 300 or 600 mg/day vs placebo for 12 weeks; no significant differences in any outcome.
- Note: Unit basis: mg of phosphatidylserine itself as declared ("Phosphatidylserine 100 mg", raw_form usually "Soy"/"Sunflower Lecithin"). "Phosphatidylserine Complex"-style rows declare the mass of a lecithin concentrate that is only a fraction PS (the label text often says 20%, 50%, 70%), so they are recorded without a dose. Soy vs sunflower source is not modeled as a form because the short raw_form strings ("Soy", "Sunflower Lecithin") would collide with unrelated lecithin/soy rows in the shared form alias map. The trial evidence mixes null (Jorissen 2001) and positive-in-subgroup (Kato-Kataoka 2010) results; PS-DHA conjugates (Vakhapova 2010, PMID 20523044) and PS plus phosphatidic acid (More 2014, PMID 25414047) are separate preparations.